Serum Adiponectin in Chinese Population and Its Correlation to Cardiovascular and Cerebrovascular Diseases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01372800

Recruitment Status : Unknown

Verified November 2011 by Xijing Hospital.
Recruitment status was: Recruiting

First Posted : June 14, 2011

Last Update Posted : November 21, 2013

Sponsor:

Information provided by (Responsible Party):

Xijing Hospital

Study Description

Brief Summary:

Adiponectin (Ad) is an abundant protein in human body, and reports have shown that it act as a novel risk factor for brain and heart ischemia injury. This 5 years follow-up study will focus on serum adiponectin concentration, activity and isoforms in Chinese population and its correlation to these diseases.

Condition or disease
Myocardial Infarction Cerebral Infarction

Detailed Description:

Adiponectin (Ad) is an abundant protein hormone regulatory of numerous metabolic processes, anti-inflammatory, vascular protective, and anti-ischemic properties. Since its 1995 discovery, Ad has garnered considerable attention for its role in diabetic and cardiovascular pathology. Clinical observations have demonstrated the association of hypoadiponectinemia in patients with obesity, cardiovascular disease, and insulin resistance. There is growing evidence supporting Ad can act as a novel risk factor for cardiovascular and cerebrovascular injury. This 5 years follow-up study will focus on serum adiponectin concentration, activity and isoforms in Chinese population and its correlation to cardiovascular and cerebrovascular diseases.

Study Design

Layout table for study information

Study Type :	Observational
Estimated Enrollment :	30000 participants
Observational Model:	Cohort
Time Perspective:	Prospective
Official Title:	Serum Adiponectin Concentration, Activity and Isoforms in Chinese Population and Its Correlation to Cardiovascular and Cerebrovascular Diseases
Study Start Date :	May 2011
Estimated Primary Completion Date :	October 2016

Groups and Cohorts

Group/Cohort
volunteer

Outcome Measures

Primary Outcome Measures :

Number of Participants with major adverse events [ Time Frame: 5 years ]
Major adverse events included but were not limited to death during the study caused by cardiovascular events or cerebrovascular events.

Secondary Outcome Measures :

blood routine, glucose and lipid profile; ECG; [ Time Frame: 5 years ]
the tests mentioned above will be taken once per year
serum adiponectin concentration, activity and isoforms [ Time Frame: 5 years ]
serum adiponectin concentration, activity and isoforms will be monitored once per year.

Biospecimen Retention: None Retained

blood

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years to 85 Years (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes
Sampling Method:	Probability Sample

Study Population

volunteer

Criteria

Inclusion Criteria:

available for 5 years of follow-up study

Exclusion Criteria:

Death caused other than cardiovascular and cerebralvascular diseases till the study ends
Floating Population
Pregnancy, lactation, or child bearing women
Tumor
Active hepatic disease or hepatic dysfunction, or AST/ALT > 1.5UNL
Severe renal dysfunction(Scr > 3 mg/dl or 264μmol/L)
Patients with any condition which, in the investigator's judgment, might increase the risk to the subject for any adverse event or abnormal laboratory finding

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01372800

Contacts

Layout table for location contacts

Contact: Ling Tao, M.D Ph.D	+86-15002955798	lingtao2006@gmail.com

Locations

Layout table for location information

China, Shaanxi
Xijing Hospital	Recruiting
Xi'an, Shaanxi, China, 710032
Contact: Ling Tao, M.D Ph.D +86-15002955798 lingtao2006@gmail.com
Principal Investigator: Ling Tao, M.D Ph.D

Sponsors and Collaborators

Xijing Hospital

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Gao C, Zhao S, Lian K, Mi B, Si R, Tan Z, Fu F, Wang S, Wang R, Ma X, Tao L. C1q/TNF-related protein 3 (CTRP3) and 9 (CTRP9) concentrations are decreased in patients with heart failure and are associated with increased morbidity and mortality. BMC Cardiovasc Disord. 2019 Jun 10;19(1):139. doi: 10.1186/s12872-019-1117-0.

Layout table for additonal information

Responsible Party:	Xijing Hospital
ClinicalTrials.gov Identifier:	NCT01372800
Other Study ID Numbers:	xj050503
First Posted:	June 14, 2011 Key Record Dates
Last Update Posted:	November 21, 2013
Last Verified:	November 2011

Keywords provided by Xijing Hospital:


adiponectin cardiovascular diseases cerebrovascular diseases

Additional relevant MeSH terms:

Layout table for MeSH terms

Cerebral Infarction Cerebrovascular Disorders Myocardial Infarction Infarction Ischemia Pathologic Processes Necrosis Myocardial Ischemia Heart Diseases	Cardiovascular Diseases Vascular Diseases Brain Infarction Brain Ischemia Brain Diseases Central Nervous System Diseases Nervous System Diseases Stroke

To Top